Metastatic Soft Tissue Sarcoma Clinical Trial
— SOURCEOfficial title:
A Study of the Safety and Efficacy of the Combination of Gemcitabine and Docetaxel With MORAb-004 in Metastatic Soft Tissue Sarcoma
Verified date | November 2016 |
Source | Morphotek |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This study is being done to see if MORAb-004 increases the effectiveness of the chemotherapies gemcitabine and docetaxel in people with metastatic Soft Tissue Sarcoma.
Status | Completed |
Enrollment | 209 |
Est. completion date | August 2, 2016 |
Est. primary completion date | August 11, 2015 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Be at least 18 years of age - Be surgically sterile or consent to use a medically acceptable method of contraception throughout the study period - Have a histologically confirmed diagnosis of mSTS as defined by the 4 specified study subgrouped - Have been treated in the metastatic setting with 0 to 2 prior systemic regimens for mSTS (Systemic treatment regimens given in the neoadjuvant setting and maintenance therapies will not be considered as regimens in the metastatic setting for the purposes of this protocol. Prior anthracycline-based regimen is allowable but not required. Subjects with extra-skeletal small round blue cell sarcomas, including rhabdomyosarcomas, must have exhausted or be intolerant of standard first line anthracycline-based chemotherapy.) - Have measurable disease, as defined by RECIST v 1.1 assess within 2 weeks of study entry and have radiologically documented disease progression greater than or equal to a 10% increase in the sum of the longest diameters of target lesions present within 6 months prior to randomization - Have tumor tissue available for TEM-1 biomarker studies - Be willing and able to provide written informed consent Exclusion Criteria: - Have received more than 2 prior systemic treatment regimens for mSTS - Have received either gemcitabine or docetaxel in any previous treatment for mSTS (regardless of the line of treatment) - Have a diagnosis of primary bone sarcoma of any histological type. - Have a history of clinically significant heart disease, or clinically significant arrhythmia on ECG within the past 6 months - Have a history of allergic reaction to prior monoclonal antibody or biologic agent - Have received previous treatment with MORAb-004 (anti-TEM-1) - Have a medical condition with a high risk of bleeding (e.g., a known bleeding disorder, a coagulopathy, or a tumor that involves the major vessels) or have a recent (within past 6 months) history of a significant bleeding event - Have undergone major surgical procedures or open biopsy, have significant traumatic injury within 30 days prior to the first date of study treatment, or have major surgical procedures anticipated during the study - Have a serious non-healing wound, an ulcer (including gastrointestinal), or a bone fracture |
Country | Name | City | State |
---|---|---|---|
Australia | Canberra Hospital | Garran | Australian Capital Territory |
Australia | Ashford Cancer Centre Research | Kurralta Park | South Australia |
Australia | Sir Charles Gairdner Hospital | Perth | Western Australia |
Australia | Royal North Shore Hospital | St. Leonards | New South Wales |
Australia | Princess Alexandra Hospital | Woolloongabba | Queensland |
Belgium | UZ Leuven Medical Oncology | Leuven | |
France | Institut Gustave Roussy | Villejuif | |
France | University of Claude Bernard | Villeurbanne | |
Italy | Istituto Ortopedico Rizzoli | Bologna | |
Netherlands | Leiden University Medical Center | Leiden | |
United States | University of Michigan Health System | Ann Arbor | Michigan |
United States | Sidney Kimmel Comprehensive Cancer Center at John Hopkins | Baltimore | Maryland |
United States | Dana-Farber Cancer Institute | Boston | Massachusetts |
United States | The University of North Carolina at Chapel Hill | Chapel Hill | North Carolina |
United States | Northwestern Memorial Hospital | Chicago | Illinois |
United States | MD Anderson Cancer Center | Houston | Texas |
United States | Mayo Clinic Jacksonville | Jacksonville | Florida |
United States | University of Miami | Miami | Florida |
United States | Mount Sinai Medical Center | New York | New York |
United States | Fox Chase Cancer Center | Philadelphia | Pennsylvania |
United States | Oregon Health and Science University | Portland | Oregon |
United States | Mayo Clinic - Rochester | Rochester | New York |
United States | Washington University | Saint Louis | Missouri |
United States | Huntsman Cancer Institute at the University of Utah | Salt Lake City | Utah |
United States | Sarcoma Oncology Center | Santa Monica | California |
United States | UCLA | Santa Monica | California |
United States | Seattle Care Alliance | Seattle | Washington |
United States | Siouxland Hematology-Oncology | Sioux City | Iowa |
United States | Moffitt Cancer Center | Tampa | Florida |
Lead Sponsor | Collaborator |
---|---|
Morphotek |
United States, Australia, Belgium, France, Italy, Netherlands,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Part 2: Radiologic Progression-free Survival (PFS) | PFS was defined as the time (in weeks) from the date of randomization to the date of first observation of disease progression according to Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) or date of death, regardless of the cause. | From date of first dose until date of first observation of disease progression, or death due to any cause (up to approximately 3 years) | |
Secondary | Part 2: Symptomatic Progression-free Survival | PFS including symptomatic progression was defined as the time (in weeks) from the date of randomization to the date of the first observation of disease progression according to RECIST 1.1, symptomatic progression, or death due to any cause. | From date of first dose until date of first observation of disease progression, symptomatic progression, or death due to any cause (up to approximately 3 years) | |
Secondary | Part 2: Overall Survival (OS) | OS was defined as the time (in months) from the date of randomization to the date of death, regardless of the cause. | From date of first dose until date of death from any cause (up to approximately 3.5 years) | |
Secondary | Part 2: Overall Response Rate (ORR) | ORR was defined as the percentage of subjects with either a complete response (CR) or a partial response (PR) based on RECIST 1.1. CR was defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to less than (<) 10 millimeter (mm). PR was defined as at least a 30 percent (%) decrease in sum of diameters of target lesions, taking as reference the baseline sum of diameters. | From date of first dose until disease progression (up to approximately 3.5 years) | |
Secondary | Part 2: Radiologic Progression-free Survival Rate (PFR) | Radiologic progression-free survival rate was defined as the percentage of subjects achieving radiologic PFS at the pre-specified time points. | Weeks 12, 24, 48 and 52 | |
Secondary | Part 2: Number of Participants Who Had Relationship Between MORAb-004 Exposures and Biomarker Levels | Up to approximately 3 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT03670069 -
Itacitinib in Treating Patients With Refractory Metastatic/Advanced Sarcomas
|
Phase 1 | |
Recruiting |
NCT05075993 -
Study of LVGN3616 and LVGN6051±LVGN7409 in Combination With Nab-Paclitaxel or Bevacizumab and Cyclophosphamide in Metastatic Solid Tumors
|
Phase 1 | |
Active, not recruiting |
NCT03793361 -
Phase II Study of Regorafenib as Maintenance Therapy
|
Phase 2 | |
Completed |
NCT03009201 -
Ribociclib and Doxorubicin in Treating Patients With Metastatic or Advanced Soft Tissue Sarcomas That Cannot Be Removed by Surgery
|
Phase 1 | |
Withdrawn |
NCT03397186 -
Immune Changes Following Trabectedin in Patients With Metastatic or Unresectable Sarcoma
|
Phase 2 | |
Recruiting |
NCT03965234 -
Pulmonary Suffusion in Controlling Minimal Residual Disease in Patients With Sarcoma or Colorectal Metastases
|
Phase 1/Phase 2 | |
Recruiting |
NCT04028063 -
Doxorubicin Plus Dual Checkpoint Blockade for Soft Tissue Sarcomas
|
Phase 2 | |
Active, not recruiting |
NCT04200443 -
Cabozantinib and Temozolomide for the Treatment of Unresectable or Metastatic Leiomyosarcoma or Other Soft Tissue Sarcoma
|
Phase 2 | |
Completed |
NCT01514188 -
Preliminary Efficacy and Safety of INNO-206 Compared to Doxorubicin in Advanced Soft Tissue Sarcoma
|
Phase 2 | |
Recruiting |
NCT05711615 -
Testing Low-Dose Common Chemotherapy (Liposomal Doxorubicin) in Combination With an Anti-Cancer Drug, Peposertib, in Advanced Sarcoma
|
Phase 1 | |
Completed |
NCT02500797 -
Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Sarcoma That Cannot Be Removed by Surgery
|
Phase 2 | |
Recruiting |
NCT03138161 -
SAINT:Trabectedin, Ipilimumab and Nivolumab as First Line Treatment for Advanced Soft Tissue Sarcoma
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03660930 -
Nab-Sirolimus and Pazopanib Hydrochloride in Treating Patients With Advanced Nonadipocytic Soft Tissue Sarcomas
|
Phase 1/Phase 2 |